Dr. Mark A. Cappel, MD

Dr. Cappel practices at Dermagnify in Ponte Vedra Beach, Florida.

Dr. Cappel's NPI, 1780668657, was assigned on December 2, 2005. Dr. Cappel graduated from Penn State College of Medicine in 2004. Dr. Cappel holds Florida license ME93687.

Dr. Cappel's primary practice is Dermagnify, at 100 Executive Way Ste 114, Ponte Vedra Beach, FL 32082-2713. The practice phone is (904) 842-3632.

Dr. Cappel's primary practice is Dermagnify in Ponte Vedra Beach, Florida. The medical group on file is Mark & Kambour Pathology.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Cappel practices. Vendor and product names are available with a free account.

Dermatology is Dr. Cappel's primary specialty in the NPI Registry, under taxonomy code 207N00000X. Dr. Cappel is board certified in dermatology by the American Board of Dermatology. Dmand AI has Dr. Cappel's licenses on file in 2 states: Florida and Minnesota.

Dmand AI lists acute skin infection, benign or precancerous skin growths, cancerous skin growth removal, cold sores or genital herpes, contact dermatitis, hives, itchy rashes and psoriasis among the conditions Dr. Cappel treats.

CMS data shows 2,945 Medicare services from Dr. Cappel across 20 procedure codes in 2024, for 497 Medicare patients. Medicare paid $133,076 for them. Every service was in an office.

CMS counts 497 Medicare patients who saw Dr. Cappel in 2024. The largest group is 65 to 74, with 253 patients. 75% of them have high cholesterol, and 67% have high blood pressure. Their average risk score is 1.12, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Cappel's median patient age at 76, with 46% women.

In 2024, Dr. Cappel wrote 1,034 Medicare Part D claims for 277 patients. 94% of them were for generic drugs. CMS names the drug for 915 of them, across 18 drugs with 11 or more claims each, at $256,267 in total drug cost. In 2023, CMS named 523 claims across 13 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 75 out of 100 for Dr. Cappel for performance year 2024, reported as part of a group. CMS counts 899 procedures of removal of skin lesions by Dr. Cappel, more than 92% of the clinicians it reports for that procedure.

Dmand AI links 40 papers to Dr. Cappel, published from 2010 to 2021. 2017 was the busiest year, with 4. The most frequent topics are Skin Neoplasms, Diagnosis, Differential and Skin. Dr. Cappel has published most often in Int J Dermatol. Dr. Cappel's most frequent co-authors are Jason C. Sluzevich, MD, Joshua M. Abzug, MD and Paul M. Hoesly, MD.

CMS Open Payments shows 138 general payments to Dr. Cappel from 27 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 99% of the total. Janssen Pharmaceuticals, Inc paid the most, $1,172.

Dr. Cappel graduated from Penn State College of Medicine in 2004. Dr. Cappel is a member of AOA, AAD and AMA.

Dr. Cappel is in network with 8 carriers, including Aetna, Elevance and Blue Cross Blue Shield of Michigan. Medicare plans come from the most carriers, 8. Check the plan with the practice before a visit.